687 related articles for article (PubMed ID: 24332869)
1. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
Magro F; Santos-Antunes J; Vilas-Boas F; Rodrigues-Pinto E; Coelho R; Ribeiro OS; Lopes S; Macedo G
J Crohns Colitis; 2014 Jul; 8(7):617-25. PubMed ID: 24332869
[TBL] [Abstract][Full Text] [Related]
2. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
Armuzzi A; Felice C; Papa A; Marzo M; Pugliese D; Andrisani G; Federico F; De Vitis I; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Dec; 7(12):e623-9. PubMed ID: 23810678
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
[TBL] [Abstract][Full Text] [Related]
4. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
5. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
[TBL] [Abstract][Full Text] [Related]
6. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
[TBL] [Abstract][Full Text] [Related]
7. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
[TBL] [Abstract][Full Text] [Related]
8. Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens G; Diamond RH; Broussard DL; Tang KL; van der Woude CJ; Rutgeerts P;
N Engl J Med; 2010 Apr; 362(15):1383-95. PubMed ID: 20393175
[TBL] [Abstract][Full Text] [Related]
9. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study.
Yamamoto T; Umegae S; Matsumoto K
Inflamm Bowel Dis; 2009 Oct; 15(10):1460-6. PubMed ID: 19266566
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for postsurgical endoscopic recurrence of Crohn's disease: no trumpets yet.
Sorrentino D; Paviotti A
Inflamm Bowel Dis; 2009 Oct; 15(10):1458-9. PubMed ID: 19462431
[No Abstract] [Full Text] [Related]
11. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
13. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
16. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
[TBL] [Abstract][Full Text] [Related]
17. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
18. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
19. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.
Regueiro M; Kip KE; Baidoo L; Swoger JM; Schraut W
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1494-502.e1. PubMed ID: 24440221
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]